Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.3.1 (
alkaline phosphatase
)
47,916
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have identified a novel chordin-like protein,
CHL2
, which is structurally most homologous to CHL/neuralin/ventroptin. When injected into Xenopus embryos,
CHL2
RNA induced a secondary axis. Recombinant
CHL2
protein interacted directly with BMPs in a competitive manner to prevent binding to the type I BMP receptor ectodomain, and inhibited BMP-dependent induction of
alkaline phosphatase
in C2C12 cells. Thus,
CHL2
behaves as a secreted BMP-binding inhibitor. In situ hybridization revealed that
CHL2
expression is restricted to chondrocytes of various developing joint cartilage surfaces and connective tissues in reproductive organs. Adult mesenchymal progenitor cells expressed
CHL2
, and its levels decreased during chondrogenic differentiation. Addition of
CHL2
protein to a chondrogenic culture system reduced cartilage matrix deposition. Consistently,
CHL2
transcripts were weakly detected in normal adult joint cartilage. However,
CHL2
expression was upregulated in middle zone chondrocytes in osteoarthritic joint cartilage (where hypertrophic markers are induced).
CHL2
depressed chondrocyte mineralization when added during the hypertrophic differentiation of cultured hyaline cartilage particles. Thus,
CHL2
may play negative roles in the (re)generation and maturation of articular chondrocytes in the hyaline cartilage of both developing and degenerated joints.
...
PMID:A novel chordin-like BMP inhibitor, CHL2, expressed preferentially in chondrocytes of developing cartilage and osteoarthritic joint cartilage. 1693 71